Commentary|Videos|November 16, 2026

Andrew Kuykendall, MD, Says Rusfertide Could Individualize PV Care

Fact checked by: Ashley Gallagher, MA

Lead VERIFY trial investigator Andrew Kuykendall, MD, explains how rusfertide could replace phlebotomy and ease fatigue in polycythemia vera (PV).

Rusftertide’s approval has given clinicians a new way to manage polycythemia vera (PV), and Andrew Kuykendall, MD, believes its value extends well beyond replacing the phlebotomy needle. Kuykendall, an associate member of the Department of Hematology at Moffitt Cancer Center, is the lead investigator on the VERIFY trial (NCT05210790).

He describes rusfertide as an alternative to phlebotomy that is more effective, more consistent, and likely to improve patient quality of life. He considers VERIFY findings highly translatable to practice because enrollment did not depend on cytoreductive therapy. About 55% of patients were receiving it—mostly with hydroxyurea, with some interferon and ruxolitinib—while 45% relied on phlebotomy alone. Kuykendall prefers not to tie rusfertide to a line of therapy. He sees candidates in several scenarios: low-risk patients who need frequent phlebotomies but struggle with the logistics, patients whose hydroxyurea is limited to lower doses by fatigue or mouth ulcers, and newly diagnosed patients started interferon who need many phlebotomies. In this last group, adding rusfertide to ropeginterferon at initiation could allow dose optimization while avoiding early phlebotomies, with the balance refined over time. The larger shift, he says, is flexibility.

“I think that it can allow us to individualize therapy for patients and ultimately maximize quality of life and the experience they have living with their disease,” Kuykendall said.

He also stressed an often underappreciated benefit: rusfertide was associated with statistically significant improvements in fatigue and disease-related symptoms. Fatigue, he noted, is among the major unmet needs in PV and the biggest predictor of poor quality of life, whether or not patients are controlled.

“The fact that we now have an agent that was shown in a randomized clinical trial to improve disease-related fatigue is, I think, massive for patients and something that really shouldn’t be understated,” Kuykendall said. Clinicians must ask patients how they feel, he added, and no longer have to ignore that part of the disease.


Related to this article